The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
BackgroundAdebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. Therefore, we, in this study, aimed to compare the survival data of adebrelimab (...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2023-05-01
|
| Serie: | Frontiers in Immunology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185577/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|